Accordingly, dynamic monitoring for the emergence of activation mutations of effectors downstream located in EGFR signaling pathway, especially RAS mutations in patients undergoing anti-EGFR therapies can be a useful tool to determine tumor response and ongoing patient care. This evidence concerns the gene EGFR and neoplasm.